Eli Lilly and Bristol-Myers Squibb announced that the companies have agreed to transfer rights to Erbitux (cetuximab) in North America, including the U.S., Canada, and Puerto Rico, from Bristol-Myers Squibb to Lilly.
Rights include, but are not limited to, full commercialization and manufacturing operational responsibilities.
|Searching for more deal information? Current Partnering offers the following options:
The companies’ decision comes after a 14-year successful collaboration, which includes Lilly’s wholly-owned subsidiary ImClone.
Bristol-Myers Squibb and Lilly will work closely to ensure a smooth transition on this important product for patients with certain advanced colorectal and head and neck cancers.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies